The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
We have studied the effect of cimetidine (800 mg.day-1) administration for three days on debrisoquine 4-hydroxylation in nine healthy extensive metabolizers. The debrisoquine metabolic ratio was significantly increased (p less than 0.01), but the new ratios remained in the extensive metabolizer range (less than 12.6). These data suggest that pre-treatment with cimetidine in usual therapeutic doses will impair debrisoquine 4-hydroxylation, but not enough to alter the apparent oxidation phenotype.
Philip
P A
PA
Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London, UK.
James
C A
CA
Rogers
H J
HJ
D000328:Adult; D002927:Cimetidine / Q000494:pharmacology*; D019389:Cytochrome P-450 CYP2D6; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003647:Debrisoquin / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism; D010641:Phenotype; D013997:Time Factors
D007546:Isoquinolines; D002927:Cimetidine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019389:Cytochrome P-450 CYP2D6; D003647:Debrisoquin